Results 81 to 90 of about 15,173,912 (274)
Journal of Molecular Biology, 2019 Factor XI (FXI), the zymogen of activated FXI (FXIa), is an attractive target for novel anticoagulants because FXI inhibition offers the potential to reduce thrombosis risk while minimizing the risk of bleeding.
M. Schaefer +4 more
semanticscholar +1 more source
Pseudo-factor-XI deficiency: effect of an inhibitor of factor XI adsorption to surface [PDF]
Blood, 1981 Abstract Recently we have described a normal plasma activity that modulates contact activation by inhibiting adsorption of factor XI to activating surfaces. Here we report the first identified case in which a patient has abnormal clotting tests due to an excess of a similar activity.
S, Schiffman +3 more
openaire +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
The safety and efficacy of novel agents targeting factor XI and XII in early phase human trials.
Seminars in Thrombosis and Hemostasis, 2019 Although anticoagulation without hemorrhage is a primary aim, this vision has remained as yet out of reach. Even despite the superior safety profile of the direct oral anticoagulants, hemorrhage remains a major risk of anticoagulation.
E. DeLoughery +4 more
semanticscholar +1 more source
Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane +19 more
wiley +1 more source
Recent Advances in the Discovery and Development of Factor XI/XIa Inhibitors
Medicinal research reviews (Print), 2018 Factor XIa (FXIa) is a serine protease homodimer that belongs to the intrinsic coagulation pathway. FXIa primarily catalyzes factor IX activation to factor IXa, which subsequently activates factor X to factor Xa in the common coagulation pathway. Growing
Rami A. Al‐Horani, Daniel K. Afosah
semanticscholar +1 more source
Factor XI Kinetics after Plasma Exchange in Severe Factor XI Deficiency [PDF]
Haemostasis, 2009 Plasma exchange in a patient with factor XI deficiency allowed the determination of the factor XI disappearance time. The decay curve showed a biphasic pattern with a t<sub>½</sub> of 12.3 h during the first 3 days, followed by a slower decay with a t<sub>½</sub> of 121 h.
I R, Nováková +3 more
openaire +2 more sources
Prominent Movement Disorders in RNU2‐2‐Related Spliceosomopathy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Pediatric movement disorders often overlap with neurodevelopmental diseases, suggesting shared molecular mechanisms. Variants in small nuclear RNA (snRNA) genes encoding spliceosome components have recently been associated with neurodevelopmental disorders, termed “RNUopathies.” We analyzed genome sequencing data from 14 patients with ...
Magdalena Krygier +6 more
wiley +1 more source
Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present)
Expert Opinion on Therapeutic Patents, 2019 Introduction: Anticoagulation without bleeding is an ideal goal in treating thrombosis, however, this goal has not been achieved. All current anticoagulants are associated with significant bleeding which limits their safe use. Genetic and pharmacological
Rami A. Al‐Horani
semanticscholar +1 more source
Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Novel composite inflammatory markers' role in stroke prognosis is understudied, and the best predictor is unclear, requiring further exploration. Objectives This study aimed to systematically evaluate the associations of 6 novel composite inflammatory markers on stroke prognosis.
Bing Wu +7 more
wiley +1 more source